Pelosi E, Fontana R
Istituto di Microbiologia, Università degli Studi di Verona, Italy.
Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):549-51. doi: 10.1007/BF01962613.
Susceptibility testing of clinical isolates of several gram-negative and gram-positive species showed LY163892 to be more active than cefaclor and cephalexin. OXA-2, TEM-1, TEM-2, PSE-1, CEP-1, CARB-3 and SHV-1 beta-lactamases showed similar activity against LY163892 and cefaclor, whereas OXA-1 hydrolyzed the latter more rapidly. Organisms producing these beta-lactamases, but not TEM-2 and CEP-1, appeared to be more susceptible to LY163892 than cephalexin, although cephalexin proved to be more resistant to beta-lactamase activity. Strains producing TEM-2 and CEP-1 were resistant to LY163892, cefaclor and cephalexin.
对几种革兰氏阴性菌和革兰氏阳性菌的临床分离株进行的药敏试验表明,LY163892比头孢克洛和头孢氨苄更具活性。OXA - 2、TEM - 1、TEM - 2、PSE - 1、CEP - 1、CARB - 3和SHV - 1β-内酰胺酶对LY163892和头孢克洛表现出相似的活性,而OXA - 1对后者的水解速度更快。产生这些β-内酰胺酶的菌株(但不包括TEM - 2和CEP - 1)似乎对LY163892的敏感性高于头孢氨苄,尽管头孢氨苄对β-内酰胺酶活性更具抗性。产生TEM - 2和CEP - 1的菌株对LY163892、头孢克洛和头孢氨苄均耐药。